Compare Organon & Co. Common Stock (OGN) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Wipro Limited — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Wipro Limited trades at $1.79 (market cap $17.45B). The key difference: Wipro Limited is far larger — about 4.8× Organon & Co. Common Stock's market cap, and Wipro Limited pays the higher dividend (4.82%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Wipro Limited for 41 Days on average.
| OGN | WIT | |
|---|---|---|
Market Cap | $3.62B | $17.45B |
Volume | 2,892,999 | 12,096,194 |
Sector | Health | Technology |
52-Week High | $13.81 | $3.06 |
52-Week Low | $5.70 | $1.61 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $11.04B | $15.54B |
Dividend Yield | 0.58% | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Wipro (WIT) trades at $1.80, up 5.88% with a bullish technical signal. The company maintains solid fundamentals with $890.88B revenue, 13.92% net margin, and $131.35B net income for 2025. Recent AI initiatives have boosted productivity equivalent to 20,000 employees. However, the stock faces mixed analyst sentiment with only 19% buy ratings and recent earnings misses.
Wipro presents a mixed investment case with reasonable valuation (P/E 13.84) and strong cash flow generation offset by earnings volatility and competitive pressures. The AI transformation offers growth potential, but investors should weigh execution risks against the company's established market position and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
